You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
BlueTurtle
New member
What great Shel Silverstein quote....anything can happen! This transplant news was unheard of yesterday...and here we are today. What hope! Same with this news today:
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
BlueTurtle
New member
What great Shel Silverstein quote....anything can happen! This transplant news was unheard of yesterday...and here we are today. What hope! Same with this news today:
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
BlueTurtle
New member
What great Shel Silverstein quote....anything can happen! This transplant news was unheard of yesterday...and here we are today. What hope! Same with this news today:
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
BlueTurtle
New member
What great Shel Silverstein quote....anything can happen! This transplant news was unheard of yesterday...and here we are today. What hope! Same with this news today:
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
BlueTurtle
New member
What great Shel Silverstein quote....anything can happen! This transplant news was unheard of yesterday...and here we are today. What hope! Same with this news today:
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.
The CF Foundation announced today it has awarded a $1.25 million milestone payment to EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics. This milestone marks <b>successful completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane conductance Regulator (CFTR) ion channel protein.</b> A mutation in the CFTR gene that codes for this channel is one of the key factors that ultimately lead to the symptoms, complications and premature mortality in people with CF.